Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials. J of Skin [Internet]. 2022 Nov. 16 [cited 2025 Apr. 16];6(6):s67. Available from: https://skin.dermsquared.com/skin/article/view/1822